All articles tagged with #duloxetine
Breckenridge Pharmaceuticals recalled certain lots of duloxetine (generic Cymbalta) after FDA testing found nitrosamine levels above the agency’s limit, affecting 30 mg (exp. Apr 2027, Lot 241180C) and two 60 mg lots (Feb 2026 Lot 230286C; Feb 2027 Lot 24072lC). Patients should contact their doctor or pharmacist and not stop taking the medication without medical guidance.
Nearly 370,000 bottles of duloxetine (Cymbalta) are being recalled after the FDA flagged levels of the nitrosamine contaminant N-nitroso-duloxetine that exceed safety limits, potentially increasing long-term cancer risk. The Class II recall covers 30 mg and 60 mg bottles with specific lot codes; no adverse effects have been reported yet. Patients should consult their healthcare provider before stopping the medication abruptly, as withdrawal can occur.
The FDA has issued a recall for the antidepressant duloxetine due to potential cancer risks. Patients using this medication are advised to consult their healthcare providers for alternative treatments and to discuss any concerns regarding their current prescriptions.
Antidepressants commonly used to treat chronic pain lack evidence as to whether or not they work, researchers have said, declaring the situation a global public health concern. A new Cochrane review has revealed there is little evidence whether or not amitriptyline and many other common antidepressants work when it comes to tackling chronic pain. The team found that many of the trials involved very small numbers of patients, making the results unreliable. Only duloxetine and milnacipran had enough evidence for the researchers to have even moderate confidence in their findings, with the drugs found to have a small to moderate effect on substantial pain relief.